Market Cap 2.79M
Revenue (ttm) 10,000.00
Net Income (ttm) -8.97M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -89,700.00%
Debt to Equity Ratio 0.00
Volume 154,000
Avg Vol 3,286,795
Day's Range N/A - N/A
Shares Out 3.53M
Stochastic %K 100%
Beta -1.69
Analysts Strong Sell
Price Target $4.50

Company Profile

Azitra, Inc., an early-stage clinical biopharmaceutical company, develops therapies for precision dermatology using engineered proteins and live biotherapeutic products to treat skin diseases. It develops ATR-12, a genetically modified strain of S. epidermidis, which is in Phase Ib clinical trial for treating Netherton syndrome, a skin disease. The company also develops ATR-04, a genetically modified strain of S. epidermidis that is in Phase 1/2 clinical trial for treating the papulopustular ras...

Industry: Biotechnology
Sector: Healthcare
Phone: 203 646 6446
Address:
21 Business Park Drive, Branford, United States
PURPLEBOY44
PURPLEBOY44 Oct. 4 at 1:25 AM
$AZTR I think they need to merge with another company and also come up with some good news. I believe they’ve got some news coming out soon. Hopefully it’s good news but they definitely need to merge with someone with capital or someone could buy them for their technology just my opinion .
0 · Reply
pbacher
pbacher Oct. 3 at 8:52 PM
$AZTR BRANFORD, Conn., Oct. 3, 2025 /PRNewswire/ -- Azitra, Inc. (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced it received a notice from the staff of NYSE American LLC (the "Exchange") that Azitra was not in compliance with the Exchange's continued listing standards under Section 1003(a)(ii) of the NYSE American Company Guide. Section 1003(a)(ii) requires a listed company to have stockholders' equity of $4 million or more if the listed company has reported losses from continuing operations and/or net losses in three of its four most recent fiscal years. Azitra is subject to the procedures and requirements of Section 1009 of the NYSE American Company Guide. Azitra has until October 31, 2025, to submit a plan (the "Plan") of actions it has taken or will take to regain compliance with the continued listing standards by April 1, 2027.
1 · Reply
Vikingsstrade
Vikingsstrade Oct. 3 at 5:47 PM
$AZTR $GIBO $LNZA $SLRX Merger news on NITO and it barely has 3 million market cap. If people find this, short sellers could get hurt alot on NITO. Small caps have been dead for a while, but NITO gives me hope that short sellers finally get what they deserve.
0 · Reply
dln101
dln101 Oct. 2 at 7:46 PM
$AZTR or $ADIL will bounce first like $ASBP $PALI 🤔💪🔥🚀
0 · Reply
1Spartantrade1
1Spartantrade1 Oct. 2 at 6:23 PM
Massive merger news 3 days ago on NITO! NITO has a low share count like TTNP (BTTC) does. TTNP ran 400% today. Can NITO also run 400%? Make sure to take profits. Lets see if NITO halts up today when people realize. $ZNB $OESX $AZTR $GIBO 🔥
0 · Reply
dln101
dln101 Oct. 1 at 2:37 PM
$AZTR time to bounce back here 🤔 $PALI style 💪🔥🚀
0 · Reply
Gconstance88
Gconstance88 Oct. 1 at 1:47 AM
$AZTR based on whats been going on in the market with these low float penny stocks its like this one is on the sidelines waiting to be put in the game... put me in coach.
0 · Reply
pbacher
pbacher Sep. 30 at 6:52 PM
$AZTR anyone still here?
1 · Reply
pbacher
pbacher Sep. 26 at 10:27 AM
$AZTR unbelievable. This is just ridiculous. I don't understand it.
0 · Reply
Latest News on AZTR
Azitra, Inc. Announces Reverse Stock Split

Aug 11, 2025, 4:15 PM EDT - 7 weeks ago

Azitra, Inc. Announces Reverse Stock Split


Azitra, Inc. to Present ATR-04 Program Update at ASCO 2025

Apr 25, 2025, 8:33 AM EDT - 5 months ago

Azitra, Inc. to Present ATR-04 Program Update at ASCO 2025


Azitra to Present at Microbiome Times Partnering Forum

Mar 12, 2025, 8:33 AM EDT - 7 months ago

Azitra to Present at Microbiome Times Partnering Forum


Azitra, Inc. to Present at the BIO CEO & Investor Conference

Feb 3, 2025, 9:05 AM EST - 8 months ago

Azitra, Inc. to Present at the BIO CEO & Investor Conference


Azitra, Inc. to Present at The Microcap Conference

Jan 27, 2025, 4:05 PM EST - 8 months ago

Azitra, Inc. to Present at The Microcap Conference


Azitra Announces Proposed Public Offering of Common Stock

Jan 14, 2025, 4:05 PM EST - 9 months ago

Azitra Announces Proposed Public Offering of Common Stock


Azitra to Present at BIO-Europe 2024

Oct 29, 2024, 9:00 AM EDT - 1 year ago

Azitra to Present at BIO-Europe 2024


Azitra, Inc. Announces Closing of Public Offering

Feb 16, 2024, 4:05 PM EST - 1 year ago

Azitra, Inc. Announces Closing of Public Offering


Azitra, Inc. Announces Pricing of Public Offering

Feb 13, 2024, 10:09 PM EST - 1 year ago

Azitra, Inc. Announces Pricing of Public Offering


Azitra to Present at the ThinkEquity Conference

Oct 16, 2023, 8:00 AM EDT - 2 years ago

Azitra to Present at the ThinkEquity Conference


PURPLEBOY44
PURPLEBOY44 Oct. 4 at 1:25 AM
$AZTR I think they need to merge with another company and also come up with some good news. I believe they’ve got some news coming out soon. Hopefully it’s good news but they definitely need to merge with someone with capital or someone could buy them for their technology just my opinion .
0 · Reply
pbacher
pbacher Oct. 3 at 8:52 PM
$AZTR BRANFORD, Conn., Oct. 3, 2025 /PRNewswire/ -- Azitra, Inc. (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced it received a notice from the staff of NYSE American LLC (the "Exchange") that Azitra was not in compliance with the Exchange's continued listing standards under Section 1003(a)(ii) of the NYSE American Company Guide. Section 1003(a)(ii) requires a listed company to have stockholders' equity of $4 million or more if the listed company has reported losses from continuing operations and/or net losses in three of its four most recent fiscal years. Azitra is subject to the procedures and requirements of Section 1009 of the NYSE American Company Guide. Azitra has until October 31, 2025, to submit a plan (the "Plan") of actions it has taken or will take to regain compliance with the continued listing standards by April 1, 2027.
1 · Reply
Vikingsstrade
Vikingsstrade Oct. 3 at 5:47 PM
$AZTR $GIBO $LNZA $SLRX Merger news on NITO and it barely has 3 million market cap. If people find this, short sellers could get hurt alot on NITO. Small caps have been dead for a while, but NITO gives me hope that short sellers finally get what they deserve.
0 · Reply
dln101
dln101 Oct. 2 at 7:46 PM
$AZTR or $ADIL will bounce first like $ASBP $PALI 🤔💪🔥🚀
0 · Reply
1Spartantrade1
1Spartantrade1 Oct. 2 at 6:23 PM
Massive merger news 3 days ago on NITO! NITO has a low share count like TTNP (BTTC) does. TTNP ran 400% today. Can NITO also run 400%? Make sure to take profits. Lets see if NITO halts up today when people realize. $ZNB $OESX $AZTR $GIBO 🔥
0 · Reply
dln101
dln101 Oct. 1 at 2:37 PM
$AZTR time to bounce back here 🤔 $PALI style 💪🔥🚀
0 · Reply
Gconstance88
Gconstance88 Oct. 1 at 1:47 AM
$AZTR based on whats been going on in the market with these low float penny stocks its like this one is on the sidelines waiting to be put in the game... put me in coach.
0 · Reply
pbacher
pbacher Sep. 30 at 6:52 PM
$AZTR anyone still here?
1 · Reply
pbacher
pbacher Sep. 26 at 10:27 AM
$AZTR unbelievable. This is just ridiculous. I don't understand it.
0 · Reply
justiceforb_85
justiceforb_85 Sep. 26 at 1:58 AM
$AZTR is the company planning a reverse stock split? When do we get the next clinical update?
1 · Reply
pbacher
pbacher Sep. 25 at 7:03 PM
$AZTR phuu, and again down 5 percent
0 · Reply
AZTR121
AZTR121 Sep. 25 at 2:19 PM
$AZTR is $3 possible ?
1 · Reply
pbacher
pbacher Sep. 24 at 12:22 PM
$AZTR Maxim lowered the firm’s price target on Azitra (AZTR) to $4 from split-adjusted $13.32 and keeps a Buy rating on the shares. The firm is citing its expectations of dilution in cutting its price target as the company addresses capital needs to advance ATR-12 and ATR-04 forward in clinical development, the analyst tells investors in a research note. Maxim adds however that Azitra’s lead program ATR-12 in Netherton syndrome reported positive initial safety data in June, and if positive, its ongoing Phase 1 trial could be a key catalyst for shares.
0 · Reply
pbacher
pbacher Sep. 24 at 12:21 PM
0 · Reply
SPYmyQQQ
SPYmyQQQ Sep. 23 at 3:03 PM
🚀 New Signal ✅ 💊 $AZTR 🗓️ Sep 23, 2025 💵 Entry: $0.7505 🎯 Target (Opt.): $0.8972 (+19.55%) 👉 Check bio for full access
0 · Reply
TwongStocks
TwongStocks Sep. 22 at 8:45 PM
One month post-RS recap. $AZTR 1:6.66 RS Aug 21, closed $0.95 Rare instance where a company did a RS that did not send the price over $1. It did trade above $1 for a few days after the RS. Post-RS high $1.40 on Aug 22. Post RS low $0.702 on Aug 26. PR on Aug 27 & it reached $1.36 that day. A swing of 93.7% Aug 26-27. Today closed $0.7506, down 21% from RS close. $ZNB 1:25 RS Aug 22, closed $2.00 Hit $3.71 the day of the RS, but traded below that since. Post RS low $1.22 Sep 2. On Sep 4 hit $3.41, a swing of 179.5% from Sep 2-4. Today closed $1.85, down 7.5% from RS close. $OESX 1:10 RS Aug 22, closed $6.21 Low of $5.60 the day of the RS, Traded above that since. Post RS high of $10 on Sept 16. Swing of 78.6% from Aug 22 - Sep 16. Today closed $8.58, up 38.16% from RS close.
0 · Reply
dln101
dln101 Sep. 22 at 6:11 PM
$AZTR its an AI name waiting to be discovered, like $POAI $SES $AXTC 🤔💪📈
0 · Reply
pbacher
pbacher Sep. 22 at 2:12 PM
$AZTR funny how the short shares gon and comes back up and gone again and the price just goes down.
0 · Reply
pbacher
pbacher Sep. 22 at 1:32 PM
$AZTR 4 cents to atl. Wow
0 · Reply
davooo
davooo Sep. 21 at 6:20 AM
$AZTR 20% short float 🤔
0 · Reply
pbacher
pbacher Sep. 19 at 3:58 PM
$AZTR oh i love it. What a bullshit -.-
0 · Reply